Ibrutinib in chronic lymphocytic leukemia and B cell malignancies

Leukemia and Lymphoma

Volumn 55, Issue 2, 2014, Pages 263-269

  Brown, Jennifer R ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BTK; CLL; Ibrutinib; NHL

Indexed keywords

DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; WALDENSTROM MACROGLOBULINEMIA;

EID: 84901775466     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.803226     Document Type: Review

References (44)

1. Honigberg LA, Smith AM, Sirisawad M, et al The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Nad Acad Sci USA 2010;107:13075-13080.
2. Herman SE, Gordon AL, Hertlein E, et al Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287-6296.
3. de Rooij M.F., Kuil A, Geest C.R., et al The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012;119:2590-2594.
4. Ponader S, Chen SS, Buggy J.J., et al The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012;119: 1182-1189.
5. Advani RH, Buggy JJ, Sharman J.P., et al Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88-94.
6. Brown JR, Byrd I, Furman R., et al Preliminary evidence of clinical activity in a phase I study of CAL-101, a potent selective inhibitor of the p110 delta isoform of phosphatidylinositol-3-kinase, in patients with relapsed or refractory chronic lymphocytic leukemia. Haematologica 2009;94(Suppl. 3):S88.
7. Friedberg JW, Sharman J, Sweetenham J., et al Inhibition of SYK with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-2585.
8. Zent CS, LaPlant BR, Johnston P.B., et al The treatment of recurrent/ refractory chroniclymphocyticleukemia/smalllymphocyticlvmphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010;116:2201-2207.
9. Fowler N, Advani R, Sharman J., et al The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Blood 2012;120(Suppl. 1): Abstract 156.
10. Wang M, Rule S, Martin P., et al Interim results of an international, multicenter, phase 2 study of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up. Blood 2012;120(Suppl. 1): Abstract 904.
11. Lenz G, Wright G, Dave S.S., et al Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
12. Davis RE, Ngo VN, Lenz G, et al Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88-92.
13. Lenz G, Davis RE, Ngo V.N., et al Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008;319:1676-1679. (Pubitemid 351432507)
14. Ngo VN, Young RM, Schmitz R, et al Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115-119.
15. Wilson W, Gerecitano J, Goy A., et al The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood 2012; 120(Suppl. 1): Abstract 686.
16. Landau DA, Carter SL, Stojanov P, et al Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013;152:714-726.
17. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-105.
18. Quesada V, Conde L, Villamor N., et al Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012;44:47-52.
19. Wang L, Lawrence MS, Wan Y, et al SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365: 2497-2506.
20. Improgo MR, Kiezun A, Wang Y., et al Functional somatic and germline variants in the NF-KB pathway in chronic lymphocytic leukemia. Blood 2012;120(Suppl. 1): Abstract 560.
21. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012;120:4684-4691.
22. Byrd J, Furman R, Coutre S., et al The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SIX) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study. Blood 2012;120(Suppl. 1): Abstract 89.
23. Hallek M, Fischer K, Fingerle-Rowson G, et al Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
24. Cheson BD, Byrd JC, Rai K.R., et al Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30:2820-2822.
25. Stilgenbauer S, Cymbalista F, Leblond V., et al Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: updated results from a phase II study of the GCLLSG and FCGCLL/MW. Blood 2012; 120(Suppl. 1): Abstract 716.
26. Brown JR, Barrientos J, Flinn I., et al The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib combined with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL, interim results of a phase Ib/n study. Haematologica 2012;97(S1): 218 (abstract 0543).
27. Fischer K, Cramer P, Busch R., et al Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29:3559-3566.
28. Jaglowski SM, Jones JA, Flynn J.M., et al A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol 2012;30(15 Suppl.): Abstract 6508.
29. Chowdhury O, Varghese A, Pattinson J., et al Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme. Br J Haematol 2011;155:519-521.
30. Burger JA, Keating MJ, Wierda W.G., et al The Btkinhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. Blood 2012;120(Suppl. 1): Abstract 187.
31. Hsu J, Gu Y, Tan S.L., et al Bruton's tyrosine kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints. Immunol Lett 2013; 150:97-104.
32. Liu J, Fitzgerald ME, Berndt M.C., et al Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 2006;108:2596-2603.
33. Farooqui M, Lozier JN, Valdez J, et al Ibrutinib (PCI 32765) rapidly improves platelet counts in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients and has minimal effects on platelet aggregation. Blood 2012;120(Suppl. 1): Abstract 1789.
34. Herman S, Farooqui M, Bezabhie R., et al In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients. Blood 2012;120(Suppl. 1): Abstract 185.
35. Wang YL, Cheng S, Ma J., et al BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Blood 2012;120(Suppl. 1): Abstract 2903.
36. Farooqui M, Aue G, Valdez J., et al Rapid decrease in overall tumor burden on ibrutinib (PCI-32765) in CLL despite transient increase in ALC indicates a significant degree of treatment induced cell death. Blood 2012;120(Suppl. 1): Abstract 2899.
37. Davids MS, Deng J, Wiestner A., et al Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 2012;120:3501-3509.
38. Zhang W, Kater AP, Widhopf GF 2nd, et al. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Nad Acad Sci USA 2010; 107:18956-18960.
39. Amrein PC, Attar EC, Takvorian T, et al Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011;17:2977-2986.
40. Brown JR, Jahn TM, Furman R.R., et al Patterns of nodal response and lymphocytosis in patients with previously treated CLL receving the selective phosphatidylinositol 3-kinase-delta (PI3K8) inhibitor, CAL-101 (GS-1101) alone or in combination with rituximab (R) or bendamustine (B). Clin Lymphoma Myeloma Leuk 2011;11(Suppl. 2):S146-S147.
41. Flinn IW, Horwitz SM, Patel M, et al Clinical safety and activity in a phase 1 trial of IPI-145, a potent inhibitor of phosphoinositide-3-kinase- δ,γ, in patients with advanced hematologic malignancies. Blood 2012;120(Suppl. 1): Abstract 3663.
42. Brown JR, Sharman JP, Harb W.A., et al Phase lb trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). J Clin Oncol 2012;30(15 Suppl.): Abstract 8032.
43. Evans E, Sheets M, Bernard H., et al Prolonged inhibition of BCR signaling and suppression of B cell lymphoma through irreversible inhibition of Bruton's tyrosine kinase. Blood 2008;112(Suppl. 1): Abstract 2608.
44. Dubovsky JA, Beckwith KA, Woyach J.A., et al Ibrutinib is an irreversible molecular inhibitor of interleuHn-2 inducible kinase: expanding therapeutic potential and modulating a Thl selective pressure in CD4 T-Cells. Blood 2012;120(Suppl. 1): Abstract 775.